Clinical Rheumatology

, Volume 37, Issue 4, pp 949–954 | Cite as

Antiphospholipid antibodies, steroid dose, arterial hypertension, relapses, and late-onset predict organ damage in a population of Colombian patients with systemic lupus erythematosus

  • Luis F Pinto-PeñarandaEmail author
  • C. Muñoz-Grajales
  • A. F. Echeverri Garcia
  • C. J. Velásquez-Franco
  • M. A. Mesa-Navas
  • M. Zuluaga Quintero
  • S. Herrera-Uribe
  • J. D. Márquez-Hernández
Original Article


Organ damage predicts mortality, increased accrual of detriment, and poor quality of life in systemic lupus erythematosus patients. The objective of this study is to determine the damage-free survival and its predictive factors in a population of Colombian subjects. The method used in this study is the retrospective follow-up of a cohort; damage was measured with SLICC/ACR index. Predictors of impairment were assessed by logistic regression and survival analysis. One hundred sixty-one individuals were included; 28.9% suffered damage, primarily neuropsychiatric, renal, and vascular. Arterial hypertension, antiphospholipid antibodies, prednisone dose, and number of relapses were all predictors of detriment. Onset after age 50 and daily prednisone dose higher than 7.5 mg determined earlier occurrence of damage.


Organ damage SLICC/ACR SDI Systemic lupus erythematosus 



The authors acknowledge the Hospital Pablo Tobón Uribe Hospital and Universidad CES.

Compliance with ethical standards

The research did not represent any risk for the patients and was approved by the Ethics committees of the Hospital Pablo Tobón Uribe and Universidad CES.




  1. 1.
    Uribe A, McGwin G Jr, Reveille J, Alarc or n GS (2004) What have we learned from a 10-year experience with LUMINA (lupus in Minories nature versus nurture) cohort? Autoimmun Rev 3(4):321–329CrossRefPubMedGoogle Scholar
  2. 2.
    Cheg M, Chiew HJ, Liu Y, Ho RC (2012) Global trend of survival and damage of systemic lupus erytematosus: meta-analysis and meta-regression of observational studies from 1950 to 2000. Without Arthritis Rheum 41(6):830–839Google Scholar
  3. 3.
    Urowitz MB, Gladman DD, Tom BD, Iba ñ and z D, Farewell VT (2008) Changing patterns in mortality and disease outcomes for patients with systemiclupus erythematosus. J Rheumatol 35:2152–2158CrossRefPubMedGoogle Scholar
  4. 4.
    Moss KE, Ioannaou And SM Sultan, HAQ I, Isenberg D. (2002) Outcome in a cohort of 300 patients with systemic lupus erythematosus attending todedicate clinic for ever two decades. Ann Rheum Dis 61(5):409–413Google Scholar
  5. 5.
    Doria A, Iaccarino L, Ghirardello A et al (2006) Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 119:700–706CrossRefPubMedGoogle Scholar
  6. 6.
    Wang C, May NE, Fortin PR (2001) The relationship between health related quality of life and disease activity and damage in lupus erythematosussistemkic. J Rheumatol 28(3):525–532PubMedGoogle Scholar
  7. 7.
    Hanly JG (1997) Disease activity, cumulative damage and quality of life in systemic lupus erythematosus: result of a cross-sectional study. Lupus 6(2):243–247 57CrossRefPubMedGoogle Scholar
  8. 8.
    Nossent J, Cikes N, Kiss E, Marchesoni A (2007) Current causes of death in systemic lupus erythematosus in Europe 2000–2004: relation to disease activity and damage accrual. Lupus 16(5):309–317CrossRefPubMedGoogle Scholar
  9. 9.
    Chambers SI, Allen E, Rahman A, Isenberg D (2009) Damage and mortality in a group of British patients with systemic lupus erythematosus followed up to ten years. Rheumatology 48(6):673–675CrossRefPubMedGoogle Scholar
  10. 10.
    Rhaman P, Gladman DD, Urowitz MB, Hallet D, Tan LS (2001) Early damage as measured by SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 10(2):93–96CrossRefGoogle Scholar
  11. 11.
    Yee CS, Hussein H, Skan J, Bowman S, Situnsayake D, Gordon C (2003) Association of damage with antibody profile, age, race, sex and disease systemic lupus erythematosus in duration. Rheumatology 42(2):276–279CrossRefPubMedGoogle Scholar
  12. 12.
    Ruiz Irastroza G, Egurvide MV, Mart í nez Berriotxoa A, Ugalde J, Aguirre C (2004) Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus. Lupus 13(12):900–905CrossRefGoogle Scholar
  13. 13.
    Vil to LM, Molina MJ, Mayor AM, Peredo RA, Santella ML, Vil to S (2006) Clinical and prognostic value of autoantibodies in Puerto Ricans Withsystemic lupus erythematosus. Lupus 15(12):892–898CrossRefGoogle Scholar
  14. 14.
    Ugarte-Gil M, Acevedo-V to squez E, Alarc or n GS, Pastor-Asurza CA, Alfaro-Lozano JL, Cucho-Venegas JM et al. The number of flares patients experience impacts on damage systemic lupus erythematosus accrual in: data from a multiethnic Latin American cohort. Ann Rheum Dis 2015; 74(6): 1019–1023.Google Scholar
  15. 15.
    Conti F, Ceccarelli F, Perricone C, Leccese I, Massaro L, Pacucci VA et al (2016) The Chronic systemic lupus erythematosus damage is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort. Lupus 25(7):719–726CrossRefPubMedGoogle Scholar
  16. 16.
    Shinjo S, Bonfa E, Wojdyla D, Borba E, Ramirez LA, Scherbarth H et al (2010) Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 62(3):855–862CrossRefPubMedGoogle Scholar
  17. 17.
    Maddison P, Farewell P, Isenberg D, Aranow C, Bae SC, Barr S et al (2002) The rate and pattern of organ damage in lateral onset systemic lupus erythematosus. J Rheum 29(5):913–917PubMedGoogle Scholar
  18. 18.
    Toloza SM, Roseman JM, Alarc or n GS, McGwin G, Uriube SA, Fessler B et al (2004) Systemic lupus erythematosus in a multiethnic US cohort(LUMINA): XXII. Predictors of time to occurrence of initial damage. Arthritis Rheum 50(10):3177–3186CrossRefPubMedGoogle Scholar
  19. 19.
    Nossent J, Rozman B, Pokorny G, Vlachoyiannopoulos P, Olessinka M, Marchesoni A et al (2010) Disease activity and damage accrual during the early course in a multinational inception cohort of patient with systemic lupus erythematosus. Lupus 19(8):949–956CrossRefPubMedGoogle Scholar
  20. 20.
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Austin A, Bell A et al (1992) Derivation of the SLEDAI. A disease activity index patients for lupus. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630–640CrossRefPubMedGoogle Scholar
  21. 21.
    Gladman D, Ginzler E, Goldsmith C et al (1992) Systemic lupus international collaborative clinics: development of a damage systemic lupuserythematosus in index. J Rheumatol 19(3):1820–1821PubMedGoogle Scholar
  22. 22.
    Bandeira M, Buratti S, Bartoli M, Gasparini C, Breda L, Pistorio A et al (2006) Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile—onset systemic lupus erythematosus. Lupus 15(8):515–520CrossRefPubMedGoogle Scholar
  23. 23.
    Reveille J, Bartolucci A, Alarcon GS (1990) Prognosis in systemic lupus erythematosus. Negative impact of increasing age onset, black race and thromobocytopenia as well as causes of death. Arthritis Rheum 33(1):37–48CrossRefPubMedGoogle Scholar
  24. 24.
    Urowitz MB, Gladman DD, Iba ñ ez D, Fortin S, Bae SC, Gordon C et al (2012) Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken) 64(17):132–137CrossRefGoogle Scholar
  25. 25.
    Gladman DD, Urowitz MB, Rhaman P, Ib ez aN D, Tam LS (2003) Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 30(9):1955–1599PubMedGoogle Scholar
  26. 26.
    Stoll T, Seifert B, Isenberg DA (1996) SLICC/ACR damage index is valid and renal and pulmonary organ score are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 35(3):248–254CrossRefPubMedGoogle Scholar
  27. 27.
    Cassano G, Roverano S, Patras S, Bellomio V, Lucero E, Berman A et al (2007) Accrual of organ damage patients over time in Argentina with systemic lupus erythematosus: a multi-centre study. Clin Rheum 26(12):2017–2022CrossRefGoogle Scholar
  28. 28.
    Nossent JC (1998) SLICC/ACR damage index in African-Caribbean patients with systemic lupus erythematosu: changes and relationship to disease activity, corticosteroid therapy and prognosis. J Rheumatol 25(4):654–659PubMedGoogle Scholar
  29. 29.
    Ruiz Arruza I, Ugarte A, Cabezas Rodriguez I, Medina J, Moran M, Ruiz-Irastorza G (2014) Glucocorticoids and irreversible damage in systemic lupus erythematosus. Rheumatology 53(8):1470–1476CrossRefPubMedGoogle Scholar
  30. 30.
    Zonana-Nacach A, Barr SD, Magder LS, Petri MA (2000) Systemic lupus erythematosus in damage and its association with corticosteroids. ArthritisRheum 43(8):1801–1808CrossRefGoogle Scholar
  31. 31.
    Petri M (1995) Musculoskeletal complications of systemic lupus erythematosus in the John Hopkins lupus cohort: an update. Arthritis Care Res 8(1):137–145CrossRefPubMedGoogle Scholar
  32. 32.
    Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM (2002) Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict illness damage. Arthritis Rheum 46(2):436–444CrossRefPubMedGoogle Scholar
  33. 33.
    Mikdashi J, Handwerger B (2004) Predictors of neuropsychiatric systemic lupus erythematosus in damage: data from the Maryland lupus cohort. Rheumatology 43(12):1555–1560CrossRefPubMedGoogle Scholar
  34. 34.
    Ruiz-Irastorza G, Egurbide MV, Ugalde J, Aguirre C (2004) High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with lupus erythematosus systemic. Arch Int Med 164(1):77–82CrossRefGoogle Scholar
  35. 35.
    Stoll T, Sutclife N, Mach J, Klaghofer R, Isenberg DA (2004) Analysis of the relationship between disease activity and damage in patients with lupuserythematosus systemic—a 5 year prospective study. Rheumatology 43(8):1039–1044CrossRefPubMedGoogle Scholar
  36. 36.
    Ugarte-Gil M, Acevedo-V to squez E, Alarc or n GS, Pastor-Asurza CA, Alfaro-Alfaro-Lozano JL, Cucho-Venegas JM et al. The number of flares patients experience impacts on damage systemic lupus erythematosus accrual in: data from a multiethnic Latin American cohort. Ann Rheum Dis 2015; 74 (6): 1019–1023.Google Scholar
  37. 37.
    Appenzeller S, Pereira DA, Costallat LTL (2008) Greater accrual damage in lateral onset systemic lupus erythematosus: a long-term follow-up study. Lupus 17(11):1023–1028CrossRefPubMedGoogle Scholar
  38. 38.
    Catoggio LJ, Soriano ER, Imamura PM, Wojdyla D, Jacobelli S, Massardo L et al (2015) Lateral onset systemic lupus erythematosus in Latin-Americans: a distinct subgroup? Lupus 24(8):788–795CrossRefPubMedGoogle Scholar
  39. 39.
    Bertoli AM, Alarcon GS, Calvo-Al Appen J, Fernandez to M, Vil to LM, Reveille JD, LUMINA study group (2006) Systemic lupus erythematosus in a multiethnic US cohort. Arthritis Rheum 54(5):1580–1587CrossRefPubMedGoogle Scholar
  40. 40.
    Thaner M, Hern to n MA, Zhang Y, Cotter D, Petri MA (2009) Prednisone, lupus activity and permanent organ damage. J Rheumatol 36(3):560–564CrossRefGoogle Scholar
  41. 41.
    Santos MJ, Vinegar F, Nero P, Barcelos F, Barcelos A, Rodrigues A et al (2009) Predictors of damage progression in Portuguese patients with systemic lupus their erythematosus. Ann N Y Acad Sci 1173(1):822–828CrossRefPubMedGoogle Scholar
  42. 42.
    Estévez-Del Toro M, Chico-Capote A, Hechavarría H, Jiménez-Paneque R, Kokuina E (2010) Daño en pacientes cubanos con lupus eritematoso sistémico: relación con características de la enfermedad. Reumatol Clin 6(1):11–15Google Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2017

Authors and Affiliations

  • Luis F Pinto-Peñaranda
    • 1
    Email author
  • C. Muñoz-Grajales
    • 1
  • A. F. Echeverri Garcia
    • 1
  • C. J. Velásquez-Franco
    • 2
  • M. A. Mesa-Navas
    • 2
  • M. Zuluaga Quintero
    • 3
  • S. Herrera-Uribe
    • 4
  • J. D. Márquez-Hernández
    • 1
  1. 1.Rheumatology DepartmentHospital Pablo Tobón UribeMedellinColombia
  2. 2.Rheumatology SectionClinica Universitaria Universidad Pontificia BolivarianaMedellinColombia
  3. 3.Internal Medicine DepartmentHospital Pablo Tobon UribeMedellinColombia
  4. 4.Hospital General de Medellin, Art MedicaMedellinColombia

Personalised recommendations